Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Neoplasms 3Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor Cancers 1Ovarian Neoplasms 1Neoplasm Metastasis 1Lethal Congenital Contracture Syndrome 2 1Head and Neck Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Breast Neoplasms 1

Interventions

Paclitaxel 68Carboplatin 64pembrolizumab 32Cyclophosphamide 32Bevacizumab 27liposomal doxorubicin 24Cisplatin 24Topotecan 21Gemcitabine 21olaparib 18fludarabine 17Taxes 16Docetaxel 15Nivolumab 14Doxorubicin 14niraparib 13veliparib 12Albumin-Bound Paclitaxel 11aldesleukin 9Filgrastim 9fludarabine phosphate 8durvalumab 8Oxaliplatin 8Fluorouracil 8Drug Therapy 8sargramostim 7Peripheral Blood Stem Cell Transplantation 7Magnetic Resonance Spectroscopy 7Leucovorin 7talazoparib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Ovarian Neoplasms × seribantumab × Clear all
NCT01209195 2016-09-08

A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers

Merrimack Pharmaceuticals

Phase 1 Completed
41 enrolled 14 charts
BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡